Non-Small Cell Lung Cancer Coverage from Every Angle

ESMO I-O 2019: Overall Survival With Nivolumab/Ipilimumab in Lung Cancer

By: Hillary Ojeda
Posted: Thursday, December 19, 2019

Based on the overall survival analysis of CheckMate 817, a treatment of flat-dose nivolumab plus ipilimumab in patients with advanced non–small cell lung cancer (NSCLC) with and without a poor performance status had “durable” outcomes. These study findings were presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2019 in Geneva by Fabrice Barlesi, MD, PhD, of the Aix-Marseille Université, and colleagues (Abstract 92O).

A total of 589 patients with previously untreated stage IV or recurrent NSCLC were enrolled in the multicohort, single-arm, phase IIIb study. Cohort A (n = 391) contained patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, whereas cohort A1 (special populations, n = 198) had an ECOG performance status of 2 or a specified comorbidity such as HIV or renal impairment. Patients received nivolumab at 240 mg every 2 weeks plus low-dose ipilimumab at 1 mg/kg every 6 weeks for up to 2 years or until disease progression.

In cohorts A and A1, the median overall survival was 17.0 months and 9.9 months, with a minimum follow-up of 21 months and 14 months, respectively. After 1 year, overall survival was 60% for cohort A and 47% for cohort A1. The cohorts had a similar safety profile, with comparable rates of treatment-related adverse events. Additionally, the median time range to onset of adverse events was similar (cohort A, 2–26 weeks;cohort A1, 2–21 weeks).

Overall survival outcomes in cohort A were similar to those in CheckMate 227, but comorbidities affected survival for patients in cohort A1.

Disclosure: The study authors’ disclosure information can be found at

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.